Clarivate Epidemiology’s coverage of asthma comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of asthma for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets of the United States, Europe, and Japan and 10 years for the other countries covered in this report. In addition to forecasting prevalent patient populations, we estimate the number of drug-treatment opportunities in specific lines of therapy in the major mature pharmaceutical markets.
Clarivate Epidemiology’s asthma forecast will answer the following questions:
In developing countries, what impact will economic growth and development have on the number of people living with asthma?
How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of asthma over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
In total, Clarivate Epidemiology forecasts 20 asthma patient populations, including the following:
Diagnosed symptomatic or medically controlled 12-month prevalent cases of asthma.
Diagnosed symptomatic or medically controlled 12-month prevalent cases of asthma by GINA treatment steps.
Diagnosed symptomatic or medically controlled drug-treated 12-month prevalent cases of asthma.
Diagnosed symptomatic 12-month prevalent cases of asthma.
Diagnosed symptomatic 12-month prevalent cases of asthma by severity.
Diagnosed medically controlled 12-month prevalent cases of asthma.
Diagnosed symptomatic or medically controlled 12-month prevalent cases by GINA treatment steps
Diagnosed symptomatic 12-month prevalent cases by symptom-based severity
Diagnosed symptomatic or medically controlled eosinophilic 12-month prevalent cases
Diagnosed symptomatic or medically controlled 12-month prevalent cases with a history of atopy
Drug-treated populations
Risk / protective factors applied to disease forecast models
Reference materials
Bibliography
Glossary
Abbreviation table
Jai Oberoi
Jai Oberoi, M.P.H., isan associate epidemiologist at Clarivate. His areas of interest are oncology and real-world data analysis. Previously, he was a research specialist at Emory University, where he analyzed whole genome/exome data. He obtained his M.P.H. in epidemiology and applied biostatistics from Columbia University, where he conducted research on the phenotypic and genotypic markers of aging.
Alexandre Vo Dupuy, Pharm.D., M.Sc.
Alexandre Vo Dupuy, M.Sc., Pharm.D., is a principal epidemiologist at Clarivate. Previously, he worked in the fields of consulting and real-world evidence and at a major pharmaceutical company. He obtained his doctor of pharmacy from Descartes University in Paris and his master’s degree in pharmacoepidemiology from the University of Bordeaux. He has worked in multiple therapy areas, with a focus on cancer epidemiology. He also codeveloped a scenario-based forecast for COVID-19.
